|
US4376110A
(en)
|
1980-08-04 |
1983-03-08 |
Hybritech, Incorporated |
Immunometric assays using monoclonal antibodies
|
|
US5204244A
(en)
|
1987-10-27 |
1993-04-20 |
Oncogen |
Production of chimeric antibodies by homologous recombination
|
|
US5652338A
(en)
|
1988-03-16 |
1997-07-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Neutrophil chemotactic factor
|
|
JPH03505037A
(ja)
|
1988-05-02 |
1991-11-07 |
大日本製薬株式会社 |
ヒト好中球走化因子ポリペプチドの製造方法
|
|
DE68919085T2
(de)
|
1988-08-29 |
1995-04-06 |
Dainippon Pharmaceutical Co |
Verfahren zur herstellung eines polypeptids welches als menschlicher neutrophiler chemotaktischer faktor aktiv ist.
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5175384A
(en)
|
1988-12-05 |
1992-12-29 |
Genpharm International |
Transgenic mice depleted in mature t-cells and methods for making transgenic mice
|
|
US5427098A
(en)
|
1988-12-22 |
1995-06-27 |
Biofield Corp. |
Noninvasive method for determining treatment based upon lesion cell proliferation measurements
|
|
GB8909218D0
(en)
|
1989-04-22 |
1989-06-07 |
Medical Res Council |
Improvements in or relating to enhancers
|
|
WO1991000906A1
(en)
|
1989-07-12 |
1991-01-24 |
Genetics Institute, Inc. |
Chimeric and transgenic animals capable of producing human antibodies
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
ES2284161T3
(es)
|
1990-01-12 |
2007-11-01 |
Amgen Fremont Inc. |
Generacion de anticuerpos xenogenicos.
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
|
AU8507191A
(en)
|
1990-08-29 |
1992-03-30 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
IE913192A1
(en)
|
1990-09-12 |
1992-02-25 |
Scripps Research Inst |
Active site of interleukin-8: polypeptide analogs and¹antibodies
|
|
ES2113940T3
(es)
|
1990-12-03 |
1998-05-16 |
Genentech Inc |
Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
|
|
US5780279A
(en)
|
1990-12-03 |
1998-07-14 |
Genentech, Inc. |
Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
|
|
US5919896A
(en)
|
1991-03-29 |
1999-07-06 |
Genentech, Inc. |
PF4A receptor
|
|
US5776457A
(en)
|
1991-03-29 |
1998-07-07 |
Genentech, Inc. |
Antibodies to human PF4A receptor and compositions thereof
|
|
ES2149772T5
(es)
|
1991-03-29 |
2008-02-16 |
Genentech, Inc. |
Receptores humanos pf4a y su utilizacion.
|
|
US5552284A
(en)
|
1991-03-29 |
1996-09-03 |
Genentech, Inc. |
Detection of interleukin-8 receptors by nudeic acid hybridization
|
|
US5543503A
(en)
|
1991-03-29 |
1996-08-06 |
Genentech Inc. |
Antibodies to human IL-8 type A receptor
|
|
US5440021A
(en)
|
1991-03-29 |
1995-08-08 |
Chuntharapai; Anan |
Antibodies to human IL-8 type B receptor
|
|
US5840856A
(en)
|
1991-03-29 |
1998-11-24 |
Genentech, Inc. |
Antibodies to a human PF4 superfamily receptor
|
|
US6087475A
(en)
|
1991-12-19 |
2000-07-11 |
Genentech, Inc. |
PF4A receptor
|
|
ES2301158T3
(es)
|
1992-07-24 |
2008-06-16 |
Amgen Fremont Inc. |
Produccion de anticuerpos xenogenicos.
|
|
US5508717A
(en)
|
1992-07-28 |
1996-04-16 |
Sony Corporation |
Computer pointing device with dynamic sensitivity
|
|
US6200558B1
(en)
|
1993-09-14 |
2001-03-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
|
|
AU6819494A
(en)
|
1993-04-26 |
1994-11-21 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US6448379B1
(en)
|
1993-09-14 |
2002-09-10 |
Chiron Corporation |
IL8 inhibitors
|
|
US5702946A
(en)
|
1994-03-03 |
1997-12-30 |
Genentech, Inc. |
Anti-IL-8 monoclonal antibodies for treatment of inflammatory disorders
|
|
US5874080A
(en)
|
1994-03-03 |
1999-02-23 |
Genentech, Inc. |
Anti-IL-8 monoclonal antibodies for treatment of asthma
|
|
GB2303238B
(en)
|
1994-04-28 |
1998-02-18 |
Music Vending Inc |
Vending system
|
|
CA2194907A1
(en)
|
1994-07-13 |
1996-02-01 |
Kouji Matsushima |
Reshaped human antibody against human interleukin-8
|
|
US5707621A
(en)
|
1994-08-31 |
1998-01-13 |
Chugai Pharmaceutical Co., Ltd. |
Supression of nephritis-induced protein excretion by anti-IL-8
|
|
AU4771696A
(en)
|
1995-01-23 |
1996-08-14 |
Regents Of The University Of California, The |
Methods for the treatment of acid aspiration-induced acute lung injury
|
|
EP0822830B1
(en)
|
1995-04-27 |
2008-04-02 |
Amgen Fremont Inc. |
Human anti-IL-8 antibodies, derived from immunized xenomice
|
|
AU2576697A
(en)
|
1996-04-19 |
1997-11-12 |
Chugai Seiyaku Kabushiki Kaisha |
Rheumatoid arthritis remedy containing anti-il-8 antibody as active ingredient
|
|
US6497878B1
(en)
|
1996-04-23 |
2002-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Treatment of cerebral disorders by inhibition of IL-8 binding to receptor
|
|
AU709108B2
(en)
|
1996-06-26 |
1999-08-19 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agent for acute lung injury resulting from indirect causes comprising anti-IL-8 antibody as active ingredient
|
|
WO1998017312A1
(en)
|
1996-10-22 |
1998-04-30 |
Chugai Seiyaku Kabushiki Kaisha |
Sepsis remedy comprising anti-il-8 antibody as active ingredient
|
|
NZ336839A
(en)
|
1997-02-21 |
2001-08-31 |
Genentech Inc |
Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies
|
|
CN1068524C
(zh)
|
1997-06-23 |
2001-07-18 |
叶庆炜 |
一种治疗顽症牛皮癣的药物
|
|
WO1999037779A1
(en)
|
1998-01-22 |
1999-07-29 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same
|
|
EP1105427A2
(en)
|
1998-08-17 |
2001-06-13 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
|
EE05627B1
(et)
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
|
US6015557A
(en)
|
1999-02-24 |
2000-01-18 |
Tobinick; Edward L. |
Tumor necrosis factor antagonists for the treatment of neurological disorders
|
|
US6419944B2
(en)
|
1999-02-24 |
2002-07-16 |
Edward L. Tobinick |
Cytokine antagonists for the treatment of localized disorders
|
|
US6419934B1
(en)
|
1999-02-24 |
2002-07-16 |
Edward L. Tobinick |
TNF modulators for treating neurological disorders associated with viral infection
|
|
US6177077B1
(en)
|
1999-02-24 |
2001-01-23 |
Edward L. Tobinick |
TNT inhibitors for the treatment of neurological disorders
|
|
US6423321B2
(en)
|
1999-02-24 |
2002-07-23 |
Edward L. Tobinick |
Cytokine antagonists for the treatment of sensorineural hearing loss
|
|
IL129180A0
(en)
|
1999-03-25 |
2000-02-17 |
Technion Res & Dev Foundation |
Method and pharmaceutical composition for wound healing
|
|
MXPA02001878A
(es)
|
1999-08-23 |
2003-08-20 |
Dana Farber Cancer Inst Inc |
Moleculas b7-4 novedosas y usos de las mismas.
|
|
PT1210428E
(pt)
|
1999-08-23 |
2015-07-21 |
Genetics Inst Llc |
Pd-1, um recetor para b7-4 e suas utilizações
|
|
CN102766210B
(zh)
|
1999-08-24 |
2015-07-08 |
E.R.施贵宝&圣斯有限责任公司 |
人ctla-4抗体及其应用
|
|
US6794132B2
(en)
|
1999-10-02 |
2004-09-21 |
Biosite, Inc. |
Human antibodies
|
|
DE19952622A1
(de)
|
1999-11-02 |
2001-05-10 |
Bayer Ag |
Verfahren zur Herstellung von rekombinantem Interleukin-8 und Interleukin-8 Muteinen
|
|
US6680209B1
(en)
|
1999-12-06 |
2004-01-20 |
Biosite, Incorporated |
Human antibodies as diagnostic reagents
|
|
US6420346B1
(en)
|
2000-02-07 |
2002-07-16 |
Rappaport Family Institute For Research In The Medical Sciences |
Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis
|
|
AR030753A1
(es)
|
2000-09-25 |
2003-09-03 |
Smithkline Beecham Corp |
Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas
|
|
US7427665B2
(en)
|
2000-12-08 |
2008-09-23 |
Alexion Pharmaceuticals, Inc. |
Chronic lymphocytic leukemia cell line
|
|
US7408041B2
(en)
|
2000-12-08 |
2008-08-05 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
|
EP1379274A4
(en)
|
2001-03-23 |
2006-02-15 |
Univ Texas |
PROCESS FOR INHIBITING ANGIOGENESIS, TUMOR GROWTH AND METASTASES WITH FULL HUMAN ANTI-IL8 AND ANTI-MUC18 IN DIFFERENT TUMOR TYPES
|
|
AU2003220439A1
(en)
|
2002-03-19 |
2003-10-08 |
Abgenix, Inc. |
Methods for treating chronic obstructive pulmonary disease (copd)
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
AU2003299641C1
(en)
|
2002-12-16 |
2016-06-02 |
Cormorant Pharmaceuticals Ab |
Human monoclonal antibodies against interleukin 8 (IL-8)
|
|
WO2004056875A1
(en)
|
2002-12-23 |
2004-07-08 |
Wyeth |
Antibodies against pd-1 and uses therefor
|
|
US20050142136A1
(en)
|
2003-10-23 |
2005-06-30 |
Lary Suva |
Anti-interleukin 8 therapy for tumor osteolysis
|
|
EA010654B1
(ru)
|
2004-11-23 |
2008-10-30 |
Пи Ай Пи Ко., Лтд. |
Вмонтированная в стену распределительная коробка водоснабжения
|
|
EP1874820A4
(en)
|
2005-04-20 |
2010-09-22 |
Amgen Fremont Inc |
HIGH AFFINE, COMPLETELY HUMAN MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-8 AND EPITOPES FOR SUCH ANTIBODIES
|
|
PL2161336T5
(pl)
*
|
2005-05-09 |
2017-10-31 |
Ono Pharmaceutical Co |
Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
|
|
CA2612241C
(en)
|
2005-07-01 |
2018-11-06 |
Medarex, Inc. |
Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
|
|
KR101586617B1
(ko)
|
2007-06-18 |
2016-01-20 |
머크 샤프 앤 도메 비.브이. |
사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
|
|
US20090028857A1
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
|
WO2009026117A2
(en)
|
2007-08-16 |
2009-02-26 |
Glaxo Group Limited |
Novel compounds
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
ES2545609T3
(es)
|
2008-08-25 |
2015-09-14 |
Amplimmune, Inc. |
Composiciones de antagonistas de PD-1 y métodos de uso
|
|
EP4209510B1
(en)
|
2008-12-09 |
2024-01-31 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
NO2504364T3
(enExample)
|
2009-11-24 |
2018-01-06 |
|
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
SI2699264T1
(en)
|
2011-04-20 |
2018-08-31 |
Medimmune Llc |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
RU2604814C2
(ru)
|
2011-07-24 |
2016-12-10 |
Кьюртек Лтд. |
Варианты гуманизированных иммуномодулирующих моноклональных антител
|
|
US9624298B2
(en)
|
2011-11-28 |
2017-04-18 |
Merck Patent Gmbh |
Anti-PD-L1 antibodies and uses thereof
|
|
US10774132B2
(en)
|
2012-01-09 |
2020-09-15 |
The Scripps Research Instittue |
Ultralong complementarity determining regions and uses thereof
|
|
WO2013106489A1
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
|
EP2844290A4
(en)
|
2012-05-01 |
2015-12-16 |
Glaxosmithkline Llc |
NOVEL ANTIBODIES
|
|
AU2013263076B2
(en)
|
2012-05-15 |
2017-08-31 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
|
|
JO3580B1
(ar)
|
2013-03-15 |
2020-07-05 |
Lilly Co Eli |
أجسام مضادة لكيموكين elr+ cxc شامل
|
|
WO2015017146A2
(en)
|
2013-07-18 |
2015-02-05 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
|
US10640574B2
(en)
|
2013-07-18 |
2020-05-05 |
Taurus Biosciences, Llc |
Humanized antibodies with ultralong complementary determining regions
|
|
WO2016044189A1
(en)
*
|
2014-09-15 |
2016-03-24 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists
|
|
EA035412B1
(ru)
|
2015-05-29 |
2020-06-10 |
Бристол-Майерс Сквибб Компани |
Антитела к ox40 и их применение
|
|
CA3016187A1
(en)
*
|
2016-03-04 |
2017-09-08 |
Bristol-Myers Squibb Company |
Combination therapy with anti-cd73 antibodies
|
|
FI3464368T3
(fi)
*
|
2016-06-02 |
2023-09-12 |
Bristol Myers Squibb Co |
Anti-pd-1-vasta-aineen käyttö yhdistelmänä anti-cd30-vasta-aineen kanssa lymfooman hoitamisessa
|
|
CN109475633A
(zh)
|
2016-06-02 |
2019-03-15 |
百时美施贵宝公司 |
在难治性霍奇金淋巴瘤中用纳武单抗阻断pd-1
|
|
KR102702675B1
(ko)
*
|
2016-06-03 |
2024-09-05 |
브리스톨-마이어스 스큅 컴퍼니 |
결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
|
|
MX2020006171A
(es)
|
2018-01-12 |
2020-09-03 |
Bristol Myers Squibb Co |
Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
|